Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage

Class of 2012 Abstract === Specific Aims: To compare and evaluate the therapies prescribed, the incidence of adverse drug events, and the time to clinical cure in transplant patients with a cytomegalovirus (CMV) infection at an academic medical center before and during the foscarnet nationwide short...

Full description

Bibliographic Details
Main Authors: Doehnert, Deborah, Hattrup, Allison, Leadbetter, Maggie, Matthias, Kathryn, Yost, Sarah
Language:en_US
Published: The University of Arizona. 2012
Subjects:
Online Access:http://hdl.handle.net/10150/614481
http://arizona.openrepository.com/arizona/handle/10150/614481
id ndltd-arizona.edu-oai-arizona.openrepository.com-10150-614481
record_format oai_dc
spelling ndltd-arizona.edu-oai-arizona.openrepository.com-10150-6144812017-08-08T03:00:30Z Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage Doehnert, Deborah Hattrup, Allison Leadbetter, Maggie Matthias, Kathryn Yost, Sarah Matthias, Kathryn Yost, Sarah College of Pharmacy, The University of Arizona treatment transplant cytomegalovirus (CMV) foscarnet Class of 2012 Abstract Specific Aims: To compare and evaluate the therapies prescribed, the incidence of adverse drug events, and the time to clinical cure in transplant patients with a cytomegalovirus (CMV) infection at an academic medical center before and during the foscarnet nationwide shortage. Methods: This study was a retrospective chart review to compare CMV treatment prescribed and clinical outcomes in pediatric and adult transplant patients at an academic medical center. Transplant patients were evaluated over a 16 month time period between December 2009 and March 2011. The average dose (mg/kg) and prevalence ganciclovir, foscarnet, and cidofovir prescribed in transplant patients with CMV infection were evaluated. Additionally, the incidence of adverse drug events including acute renal dysfunction and myelosuppression were characterized. Main Results: There were 30 subjects diagnosed with CMV disease during the evalutaion period. Of all of the patients treated for CMV before the shortage, 79% received ganciclovir, 43% received foscarnet, and 21% received cidofovir. Following the shortage in September 2010, the usage of the antiviral agents changed to 100%, 25%, and 13% respectively. Overall the usage of ganciclovir increased while the usage of foscarnet decreased when there was a shortage of medication. Conclusions: The antiviral prescribing patterns changed significantly during the foscarnet shortage. The average dose and incidence of ganciclovir increased which likely contributed to serious adverse events. Due to the limited amount of patients treated for CMV and the short time frame, clinical cure could not be determined at this time. Drug shortages are a serious problem and significantly influence patient outcomes. 2012 text Electronic Report http://hdl.handle.net/10150/614481 http://arizona.openrepository.com/arizona/handle/10150/614481 en_US Copyright © is held by the author. The University of Arizona.
collection NDLTD
language en_US
sources NDLTD
topic treatment
transplant
cytomegalovirus (CMV)
foscarnet
spellingShingle treatment
transplant
cytomegalovirus (CMV)
foscarnet
Doehnert, Deborah
Hattrup, Allison
Leadbetter, Maggie
Matthias, Kathryn
Yost, Sarah
Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage
description Class of 2012 Abstract === Specific Aims: To compare and evaluate the therapies prescribed, the incidence of adverse drug events, and the time to clinical cure in transplant patients with a cytomegalovirus (CMV) infection at an academic medical center before and during the foscarnet nationwide shortage. Methods: This study was a retrospective chart review to compare CMV treatment prescribed and clinical outcomes in pediatric and adult transplant patients at an academic medical center. Transplant patients were evaluated over a 16 month time period between December 2009 and March 2011. The average dose (mg/kg) and prevalence ganciclovir, foscarnet, and cidofovir prescribed in transplant patients with CMV infection were evaluated. Additionally, the incidence of adverse drug events including acute renal dysfunction and myelosuppression were characterized. Main Results: There were 30 subjects diagnosed with CMV disease during the evalutaion period. Of all of the patients treated for CMV before the shortage, 79% received ganciclovir, 43% received foscarnet, and 21% received cidofovir. Following the shortage in September 2010, the usage of the antiviral agents changed to 100%, 25%, and 13% respectively. Overall the usage of ganciclovir increased while the usage of foscarnet decreased when there was a shortage of medication. Conclusions: The antiviral prescribing patterns changed significantly during the foscarnet shortage. The average dose and incidence of ganciclovir increased which likely contributed to serious adverse events. Due to the limited amount of patients treated for CMV and the short time frame, clinical cure could not be determined at this time. Drug shortages are a serious problem and significantly influence patient outcomes.
author2 Matthias, Kathryn
author_facet Matthias, Kathryn
Doehnert, Deborah
Hattrup, Allison
Leadbetter, Maggie
Matthias, Kathryn
Yost, Sarah
author Doehnert, Deborah
Hattrup, Allison
Leadbetter, Maggie
Matthias, Kathryn
Yost, Sarah
author_sort Doehnert, Deborah
title Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage
title_short Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage
title_full Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage
title_fullStr Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage
title_full_unstemmed Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage
title_sort evaluation of cytomegalovirus treatment in transplant patients before and during the foscarnet nationwide shortage
publisher The University of Arizona.
publishDate 2012
url http://hdl.handle.net/10150/614481
http://arizona.openrepository.com/arizona/handle/10150/614481
work_keys_str_mv AT doehnertdeborah evaluationofcytomegalovirustreatmentintransplantpatientsbeforeandduringthefoscarnetnationwideshortage
AT hattrupallison evaluationofcytomegalovirustreatmentintransplantpatientsbeforeandduringthefoscarnetnationwideshortage
AT leadbettermaggie evaluationofcytomegalovirustreatmentintransplantpatientsbeforeandduringthefoscarnetnationwideshortage
AT matthiaskathryn evaluationofcytomegalovirustreatmentintransplantpatientsbeforeandduringthefoscarnetnationwideshortage
AT yostsarah evaluationofcytomegalovirustreatmentintransplantpatientsbeforeandduringthefoscarnetnationwideshortage
_version_ 1718512535801430016